| Abstract |
Abstract：Objective To investigate the effects of aripiprazole on the glycolipid metabolism and fibroblast growth factor 21 in schizophrenic patients with overweight. Methods Schizophrenic patients with overweight who were admitted to our hospital from 2017 June to month 2019 June were selected, including the control group (44 cases) and the study group (45 cases). The control group was treated orally with olanzapine at an initial dose of 5mg/d, and the dose was gradually increased to 10-20 mg/d within 2-3 weeks of treatment but not exceeded 20mg/d. The study group adopted the oral administration o aripiprazole at a initial dose of 5mg/d, and the dose of aripiprazole was gradually increased to 20mg/d within 2-3 weeks. Both groups were treated for 12 weeks. Then, we compared the changes of clinical symptoms, blood glucose and lipid levels, BMI and FGF-21 levels in the two groups before and after treatment and analyzed the correlation between FGF-21 and the above metabolic indexes. Results All positive and negative syndrome scale （PANSS）scores in the two groups were lower after treatment than before treatment, and all scores in the study group were lower than those in the control group ,and the differences were statistically significant (P<0.05). After treatment, the levels of FPG and FGF-21, BMI, the levels of TC, TG and LDL-C in the control group were higher than those before treatment, and the differences were statistically significant (P<0.05). There was no statistically significant difference of the above indexes in the study group after and before treatment (P >0.05). Pearson correlation analysis showed that the changes in FGF-21 in the control group were positively correlated with the changes in FPG, BMI, TC, TG and LDL-C. Conclusion Aripiprazole in the treatment of schizophrenia with overweight can promote glucose and lipid metabolism, BMI and FGF-21 level to be in a stable state as well as improving the clinical symptom scores of patients.
|